The earnings call highlighted significant progress in drug development, financial management, and strategic partnerships, with a strong focus on advancing key drug applications and developing the Hope Therapeutics network. Despite increased net losses and regulatory challenges, the company's strategic moves and financial improvements suggest a positive outlook.

Company Guidance

During the NRx Pharmaceuticals Q2 2025 earnings call, the company provided several key metrics and guidance. The company has reduced its quarterly operating loss by approximately 50% year-over-year, a significant achievement in their financial management. They have engaged in three drug approval applications and filed over 80,000 pages of regulatory data in the last quarter. Additionally, the company reported a net loss of $17.5 million for the quarter, driven largely by a $12 million non-cash charge related to convertible notes and warrants. However, their loss from operations improved by over 47% compared to the previous year, indicating a focus on cost reduction and efficient operations. The company also strengthened its balance sheet by closing a registered direct offering, raising $6.5 million, and expects its current cash position to support operations well into 2026. Key milestones also included the FDA's grant of a PDUFA fee waiver, saving $4.3 million, and securing long-term healthcare specialist investors who have committed to a 1-year lockup agreement.

Reduction in Operating Loss

NRx Pharmaceuticals reduced its quarterly operating loss by approximately 50% year-over-year, marking a significant improvement in financial performance.

Progress on Drug Approval Applications

NRx Pharmaceuticals is advancing three drug approval applications, including NRX-100 and NRX-101, with NRX-100 receiving a major expansion of the Fast Track designation from the FDA.

Strengthening of Balance Sheet

The company added long-term healthcare specialist investors with a 1-year lockup agreement, avoiding dilutive features, and reduced the burden of convertible debt.

PDUFA Fee Waiver

The FDA granted a PDUFA fee waiver, saving the company $4.3 million in filing fees, highlighting the drug's importance to public health.

Hope Therapeutics Network Development

NRx is finalizing the purchase of its first interventional psychiatry clinics, with state regulatory approval now in hand, and anticipates strong revenue and EBITDA growth.

Significant Funding Secured

NRx closed a direct offering, raising $6.5 million without warrants or pricing resets, supporting operations into 2026.

NRX Pharmaceuticals (NRXP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NRXP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	0.04 / -	-0.15	―	―	―
Aug 19, 2025	2025 (Q2)	-0.15 / -0.98	-0.75	-30.67% (-0.23)	―
May 15, 2025	2025 (Q1)	-0.28 / -0.34	-0.74	54.05% (+0.40)	―
Mar 17, 2025	2024 (Q4)	-0.37 / -0.72	-0.5	-44.80% (-0.22)	―
Nov 14, 2024	2024 (Q3)	-0.56 / -0.15	-0.7	78.57% (+0.55)	―
Aug 13, 2024	2024 (Q2)	-0.69 / -0.75	-1.2	37.50% (+0.45)	―
May 14, 2024	2024 (Q1)	- / -0.05	-1.6	96.88% (+1.55)	―
Apr 01, 2024	2023 (Q4)	-0.55 / -0.74	-1.6	53.75% (+0.86)	―
Nov 13, 2023	2023 (Q3)	-1.10 / -0.70	-1.4	50.00% (+0.70)	―
Aug 14, 2023	2023 (Q2)	-1.33 / -1.20	-1.1	-9.09% (-0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NRXP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 19, 2025	$2.50	$2.62	+4.80%
May 15, 2025	$2.40	$2.45	+2.08%
Mar 17, 2025	$2.35	$2.05	-12.77%
Nov 14, 2024	$1.16	$1.19	+2.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does NRX Pharmaceuticals (NRXP) report earnings?

NRX Pharmaceuticals (NRXP) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).

What is NRX Pharmaceuticals (NRXP) earnings time?

NRX Pharmaceuticals (NRXP) earnings time is at Nov 17, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NRXP EPS forecast?

NRXP EPS forecast for the fiscal quarter 2025 (Q3) is 0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing